Evaluation of Subtractive Immunopheresis for Treatment of Hormone-Refractive Advanced Breast Cancer - Abstract:
Immunicom is focusing its clinical efforts on validating a first-of-its-kind, breakthrough immunotherapy device for
treating a wide range of solid tumor cancers. The device, a subtractive immunopheresis column, specifically
reduces circulating soluble receptors for TNF-α (sTNF-Rs) that inhibit TNF-α’s tumoricidal and
immunomodulatory activity . This therapeutic approach is designed to enhance the patient’s own innate humoral
immune response. Immunicom’s goal is to demonstrate this immunotherapy option for patients with
refractory/late stage cancers, that provides more effective outcomes in terms of progression free survival, while
maintaining quality of life measures while on therapy. Immunicom’s clinical program is to develop its
immunopheresis technology, in combination with best treatment practices for cancer patients, using today’s most
advanced therapy options.
Immunicom is proposing a trial of the LW-02 immunopheresis device, at Baylor College of Medicine, for treating
refractory, metastatic hormone resistant breast cancer. Patients with ER+/Her2- breast cancers that have failed
both hormonal therapy, and chemotherapy, often have few choices for continuing therapy, resulting in an
unacceptably poor 5 year outcome for most of these patients.
Immunicom is proposing an exploratory study in 12 subjects to primarily evaluate safety and tolerability of its
immunotherapy LW-02 device in this breast cancer population. Efficacy will focus on pull down of sTNF-Rs from
the patient’s circulating blood. Breast cancer patients that have failed at least two lines of hormone therapy, and
one to two lines of chemotherapy will be recruited to receive monotherapy with the LW-02 device, over a four
week period, then in combination with eribulin chemotherapy, for an additional 12 weeks. Throughout treatment,
patients will be monitored for reduction of circulating sTNF-Rs and adverse events. Objective response/clinical
benefit will be exploratory; quality-of-life/clinical function, circulating tumor cells and markers of an immunologic
response (including in tissue) will be evaluate too. Clinical response to treatment/tumor burden will be monitored
by RECIST v1.1/iRECIST criteria (MRI/CT). Follow-up for up to 1 year will include evaluating subjects for
progression free survival (PFS), best overall response (BOR), overall response rate (ORR), and overall survival.
This exploratory study will provide critical safety and effectiveness data in refractory ER+/HER2- breast cancer,
for Immunicom to pursue a larger efficacy study in this specific cohort of patients and expand on the encouraging
body of safety, tolerability and effectiveness data emanating from ongoing studies in TNBC, NSCLC, melanoma
and other solid tumor. This trial will demonstrate if immunopheresis could be a therapeutic option for treating
refractory, hormone resistant breast cancer, alone or with chemotherapy regimens. With breast cancer the
second most common cancer and leading cause of death in women, additional therapeutic options are needed
to provide better outcomes for patients with advanced disease.
